StockData
MiniMed Group, Inc. logo

MiniMed Group, Inc. (MMED) company profile

MMEDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 13/3050% below fair value
$17.78−0.87 (-4.66%)

Close on Nov 17, 2026Market cap $5.00BP/E –Yield –

About MiniMed

Surgical & Medical Instruments & Apparatus, SIC 3841

MiniMed Group, Inc. develops, manufactures, and sells medical technologies for diabetes care. Its primary offerings comprise automated insulin delivery systems, smart multiple daily injection devices, continuous glucose monitoring sensors, smart insulin pens, and consumable supplies like infusion sets and reservoirs. The company also provides therapy management software and mobile applications that coordinate glucose sensing with algorithmic insulin dosing. MiniMed provides these solutions to people with type 1 and type 2 diabetes requiring intensive insulin treatment, reaching patients through durable medical equipment providers and retail pharmacies upon prescription from healthcare professionals.

The enterprise operates internationally, providing insulin pump solutions to users across more than 80 countries. Its operational infrastructure includes two primary manufacturing and distribution facilities located in California and Puerto Rico, alongside an intellectual property base of over 2,000 patents and patent applications worldwide. MiniMed maintains its corporate headquarters in Northridge, California.

Summary of the business section of MiniMed's latest annual report, written by StockData.

Company profile

Company

Legal name
MiniMed Group, Inc.
Headquarters
Northridge, CA
Address
18000 Devonshire St. 91325
Phone
(763) 222-9423
Employees
8,000, Apr 24, 2026
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Minneapolis, Minnesota

Stock & identifiers

Ticker
MMED
Exchange
Nasdaq
IPO date
Mar 6, 2026
Shares outstanding
281M, Sep 3, 2026
Filer category
Non-accelerated filer
SEC CIK
2062583
CUSIP
60365F109
ISIN
US60365F1093
FIGI
BBG01Z6N2YW2
Share class FIGI
BBG01Z6N2ZV0
LEI
254900MS5BIVZH51VD96
EIN
33-3985981

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Que DallaraChief Executive Officer, Director884,749
Ali DianatyEVP Ch. Prod. & Tech Officer325,817
Gillian ChandrasenaSVP, Chief HR Officer174,545
Sheila A. DentonSVP, Gen. Counsel & Corp. Sec.58,939
Courtney Nelson WillsSVP, Gen. Counsel, Corp. Sec.136,384
Chad SpoonerEVP, Chief Financial Officer362,707
John GyurciVP, Chief Accounting Officer39,941
Christopher EsoPresident–
Kevin E. LoftonDirector40,409
Amy BrickerDirector11,877
Robert (Bob) HopkinsDirector11,877
David J. EndicottDirector15,169
D. Keith GrossmanDirector25,684
Timothy A. WicksDirector25,684
Glenn A. EisenbergDirector25,684
Scott T. CundyDirector–
Linnea BurmanDirector–
Brett A. WallDirector–
Laura MauriDirector–
Matthew R. WalterDirector–
Brian SandstromDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$8.43M$4.38M$3.82M$71$93

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Que Dallara
Chief Executive Officer
$810.77K$965.00K$3.35M$3.22M$88.11K$8.43M-0%
Chad Spooner
Executive Vice President, Chief Financial Officer
$519.23K$970.00K$4.89M$647.91K$43.99K$7.07M–
Ali Dianaty
Executive Vice President, Chief Product & Technology Officer
$591.44K$907.39K$1.31M$959.35K$66.14K$3.84M+56%
Courtney Nelson Wills
Senior Vice President, General Counsel
$462.67K$330.00K$321.60K$593.46K$57.51K$1.77M+46%
Gillian Chandrasena
Senior Vice President, Chief Human Resources Officer
$449.73K$835.00K$796.35K$492.18K$32.56K$2.61M+42%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 6, 2026
Offer price
$20.00
Securities offered
28,000,000
Gross proceeds
$560.00M
Exchange
Nasdaq
Lock-up ends (est.)
Sep 2, 2026

“The initial public offering price per share of our common stock is $20.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 14, 2026MergerRegistration of securities for a merger or exchange offer (S-4)
Mar 9, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 6, 2026IPOInitial public offering priced (424B4 prospectus)
Mar 5, 2026ListingRegistration of securities on an exchange (Form 8-A)
May 30, 2025Name changeName changed from MDT Sub Holdings, Inc. to MiniMed Group, Inc.

See a number that looks wrong?